Compare VanEck Video Gaming and eSports ETF (ESPO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Video Gaming and eSports ETF vs Novo Nordisk A/S — how do they compare? VanEck Video Gaming and eSports ETF trades at $91.98, while Novo Nordisk A/S trades at $51.49 (market cap $222.24B). The key difference: Novo Nordisk A/S pays a 3.56% dividend while VanEck Video Gaming and eSports ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, VanEck Video Gaming and eSports ETF nearer its low. Which is the better fit depends on your goals.
| ESPO | NVO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $122.30 | $71.70 |
52-Week Low | $85.25 | $35.29 |
Market Cap | — | $222.24B |
Enterprise Value | — | $241.20B |
Dividend Yield | — | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESPO trades at $91.98, up 0.47% today, with technical indicators showing a bullish trend supported by moving averages. The ETF benefits from positive sentiment around AI-driven profit potential in the gaming industry. Recent institutional buying by Assetmark Inc. highlights growing confidence in the digital entertainment sector's growth prospects.
The outlook remains positive given AI's potential to boost gaming industry profits by $22 billion, though risks include sector competition and market volatility. Current technical strength near key support levels suggests potential for continued upward momentum if broader market conditions remain favorable.
Novo Nordisk (NVO) trades at $51.52, up 4.99% in the last session, with strong technical momentum and bullish moving averages. The company maintains robust fundamentals, including a 37.2% net income margin and consistent earnings beats in recent quarters. Recent EU approval for the Wegovy weight-loss pill (Reuters, 2026-07-15) reinforces its leadership in GLP-1 therapies, though competition is intensifying.
Outlook remains positive given solid cash flow growth and analyst support, but risks include pricing pressure from generics and slowing prescription trends. The stock's valuation at a P/E of 12.14 offers relative value in the pharma sector, with upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Video Gaming and eSports ETF
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
